Table 2 Therapy
Participants who received concurrent chemoradiotherapy—N (%) | Prior scans | Subsequent scans† |
|---|---|---|
Chemotherapy Neoadjuvant—N (%) | ||
Carboplatin/paclitaxel | 1 (11%) | 3 (33%) |
Cisplatin/fluorouracil | 0 | 1 (11%) |
Other | 0 | 0 |
Radiotherapy in concurrent chemoradiotherapy—N (%) | 1 (11%) | 4 (44%) |
Radiotherapy dosage, Gray—N (%) | ||
< 41.4 | 0 | 2 (22%) |
< 40 | 0 | 0 |
40– < 41.4 | 0 | 2 (22%) |
41.4–50.4 | 1 (11%) | 2 (22%) |
> 50.4 | 0 | 0 |
Not reported | 0 | 0 |
Participants with any therapies—N (%) | ||
Surgery | 2 (22%) | 5 (56%) |
Interventional radiology | 0 | 1 (11%) |
Systematic therapy—N (%) | ||
Immunotherapy | 0 | 2 (22%) |
Targeted therapy—N (%) | ||
Anti-angiogenic therapy | 1 (11%) | 0 |
Other systemic anticancer therapy/chemotherapy | 2 (22%) | 1 (11%) |